• In March 2026, Stryker disclosed a major cyberattack linked to the Iran-associated Handala group that disrupted its global Microsoft-based systems, wiping data on hundreds of thousands of devices and interrupting manufacturing, shipping and order processing across dozens of countries.
• The incident highlights how cybersecurity resilience has become a critical operational factor for large medtech companies whose connected platforms and hospital-facing digital ecosystems, such as Stryker’s new SmartHospital Platform, increasingly underpin everyday patient care.
• We’ll now examine how this large-scale cyberattack and resulting operational disruption could influence Stryker’s previously positive investment narrative.

Rare earth metals are the new gold rush. Find out which 29 stocks are leading the charge.

Stryker Investment Narrative Recap

Stryker’s long term appeal rests on its scale in medtech, exposure to rising procedure volumes, and a growing digital and robotics portfolio. The Iran linked cyberattack is now the most important near term swing factor, because it directly affects manufacturing, shipping and order processing, while also sharpening the focus on cybersecurity as a core operational risk alongside existing pressures like tariffs and regulatory delays.

Against that backdrop, the new SmartHospital Platform announcement feels especially relevant: it pushes Stryker deeper into connected, software heavy hospital infrastructure just as the company is dealing with a Microsoft based systems breach. For investors watching product catalysts such as Mako and broader digital health ambitions, SmartHospital underscores both the upside from deeper integration into hospital workflows and the parallel need for resilient, secure IT across those offerings.

Yet beneath the innovation story, the scale of the recent cyberattack introduces an additional layer of operational risk that investors should be aware of...

Stryker's narrative projects $30.4 billion revenue and $5.4 billion earnings by 2028. This requires 8.4% yearly revenue growth and about a $2.5 billion earnings increase from $2.9 billion today.

Uncover how Stryker's forecasts yield a $424.90 fair value, a 26% upside to its current price.

Exploring Other Perspectives

Five members of the Simply Wall St Community currently see Stryker’s fair value between US$347 and US$424.90, underscoring how far individual views can stretch. You will want to weigh those opinions against the very real risk that a prolonged cyber related disruption could sit on top of existing supply chain and regulatory challenges, with implications for how reliably Stryker can translate its product pipeline into future performance.

Explore 5 other fair value estimates on Stryker - why the stock might be worth as much as 26% more than the current price!

Reach Your Own Conclusion

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Stryker research is our analysis highlighting 4 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Stryker research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Stryker's overall financial health at a glance.

Want Some Alternatives?

Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

• AI is about to change healthcare. These 33 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• The future of work is here. Discover the 30 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• Explore 24 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.